Anika Therapeutics (ANIK)
(Real Time Quote from BATS)
$27.60 USD
+0.04 (0.15%)
Updated Jul 22, 2024 12:30 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIK 27.60 +0.04(0.15%)
Will ANIK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIK
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Other News for ANIK
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics reports inducement grants under Nasdaq listing rule
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company’s Full Potential
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)